Immunovaccine Announces a Non-Brokered Private Placement of $3.2 million

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE,
PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR
IN PART, IN OR INTO THE UNITED STATES.


Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX VENTURE:IMV)
announces its intention to complete a non-brokered private placement of at least
8 million common shares of the Company (the "Common Shares"), at a price of
$0.40 per Common Share for minimum gross proceeds of $3.2 million (the
"Offering").


The Offering is expected to close on or about November 15, 2013, subject to the
satisfaction of all necessary regulatory approvals, as well as to the
satisfaction of customary closing conditions. 


Net proceeds from the Offering will be used for general corporate purposes.

The Offering will be made as a private placement, exempt from prospectus and
registration requirements of applicable securities laws and the common shares to
be issued will be subject to a four-month hold period.


The securities described in this offering have not been, and will not be,
registered under the United States Securities Act of 1933, as amended (the "U.S.
Securities Act"), or any state securities laws, and accordingly, may not be
offered or sold within the United States or to "U.S. Persons", as such term is
defined in Regulation S promulgated under the U.S. Securities Act ("U.S.
Persons") except in compliance with the registration requirements of the U.S.
Securities Act and applicable state securities requirements or pursuant to
exemptions therefrom. This press release does not constitute an offer to sell or
a solicitation of an offer to buy any of the Company's securities in the United
States or to U.S. Persons, nor shall there be any sale of these securities in
any state or jurisdiction in which the offer, solicitation or sale would be
unlawful.


About Immunovaccine www.imvaccine.com

Immunovaccine Inc. develops cancer therapies, infectious disease vaccines and
animal health products. The Company's DepoVax(TM) platform is a patented
formulation that provides controlled and prolonged exposure of antigens plus
adjuvant to the immune system. Immunovaccine has advanced two DepoVax(TM)-based
cancer vaccines through Phase I human clinical trials, with Phase II trials
beginning in early 2014. The Company is also advancing a broad infectious
disease pipeline including vaccines for malaria, respiratory syncytial virus
(RSV) and anthrax. 


This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the Company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release. 


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Immunovaccine Inc.
Kimberly Stephens
Chief Financial Officer
(902) 492-1819
kstephens@imvaccine.com


Vida Strategic Partners (media)
Tim Brons
(415) 675-7402
tbrons@vidasp.com

(TSXV:IMV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024